
CCC 2010



# CV QUEST 2010:

A Glimpse into the Future...
The Next Decade

**CO-CHAIRS:** 

Milan Gupta, MD, FRCPC Subodh Verma, MD, FRCSC

Sunday, October 24, 2010

9:30 a.m. – 10:00 a.m. Breakfast and Registration

10:00 a.m. - 12:00 p.m. Accredited Symposium

LOCATION:

Palais des congrès de Montréal Room 517C



www.ccrnmd.com

WHO SHOULD ATTEND: Cardiologists, surgeons, internal medicine specialists, endocrinologists, primary care physicians, fellows, residents, nurses interested in these disciplines.

### LEARNING OBJECTIVES:

Throughout and following this session, the learner will be able to:

- 1. discuss the potential role of prevention of heart failure
- 2. evaluate the role of drugs and devices in the management of heart failure in the future
- debate the role of primary prevention of risk factors versus intervention once risk factors are established
- 4. explore the potential for percutaneous valve technology as an alternative to open surgical intervention
- discuss the potential role of personalized genetics to guide individualized risk stratification and drug selection

This session has been co-developed by the Canadian Cardiovascular Society and the Canadian Cardiovascular Research Network (CCRN).



### PROGRAM OVERVIEW:

Four internationally recognized experts will share their forecasts on the practice of cardiovascular medicine in the year 2020. Despite recent advances, heart failure and CAD interventions remain challenged by unacceptably high morbidity and mortality. We will discuss the role of primary prevention, drugs and devices in the management of heart failure. Lifestyle and pharmacologic management will be considered as well as their effect on CAD prevention. Environmental and metabolic factors will be considered. Treatment for valvular heart disease remains challenging particularly when surgical intervention is required in patients with significant co-morbidities. The future of percutaneous valve replacement as an effective therapy for aortic valve disease will be compared with surgical valve replacement. Finally, pharmacogenomics is rapidly expanding, and the promise of tailored therapy has been with us for the past decade. Customized treatments that offer the most effective therapy with the least potential for toxicity will be discussed.

#### To register on-line for this symposium, please visit the CCRN website at www.ccrnmd.com

**Co-Chairs:** 



Milan Gupta, MD, FRCPC Associate Clinical Professor of Medicine. McMaster University Assistant Professor of Medicine, University of Toronto Division of Cardiology, William Osler Health Centre. Brampton, Ontario



**Faculty:** 

Clyde W. Yancy, MD, FACC, FAHA, MACP President, American Heart Association, 2009-2010 Medical Director **Baylor Heart and Vascular Institute** Chief, Cardiothoracic Transplantation **Baylor University Medical Center** Dallas, Texas



Robert M. Califf, MD **Duke Translational Medicine Institute** DTMI Director Donald F. Fortin. M.D. Professor of Cardiology, School of Medicine, Vice Chancellor for Clinical Research. Durham, North Carolina



With special quest:

Subodh Verma, MD, PhD, FRCSC, FAHA Cardiac Surgeon St-Michael's Hospital Associate Professor University of Toronto Canada Research Chair in Atherosclerosis Director, Traineeship in Atherosclerosis Toronto, Ontario

Charles R. Kerr, MD, FRCPC



President of the Canadian Cardiovascular Society; Professor, University of British Columbia;

Staff Cardiologist, Electrophysiologist, St. Paul's Hospital, Vancouver, BC

John G. Webb, MD, FACC McLeod Professor of Heart Valve Intervention. University of British Columbia Director of Cardiac Catheterization and Interventional Cardiology Research, St. Paul's Hospital Vancouver, British Columbia



Robert Hegele, MD, FRCPC, FACP, FAHA, FCAHS Jacob J. Wolfe Distinguished Medical Research Chair Edith Schulich Vinet Canada Research Chair in Human Genetics, Tier I Martha G. Blackburn Chair in Cardiovascular Research Director London Regional Genomics Centre Scientist, Vascular Biology Research Group, Robarts Research Institute Distinguished University Professor, Departments of Medicine (Division of Endocrinology) and Biochemistry, University of Western Ontario London, Ontario

**AGENDA:** 

10:00 a.m. - 12:00 p.m. **Opening Remarks** Dr. Milan Gupta and Dr. Charles Kerr The Heart Failure Beast: Will we conquer it by 2020? Dr. Clyde Yancy Intervention vs. Prevention. Will the landscape change by 2020? Dr. Robert Califf An Obituary to Open Valve Replacement by 2020? Dr. John Webb Pharmacogenomics: Will "smart" therapy come of age by 2020? Dr. Robert Heaele AII Discussion Dr. Subodh Verma **Closing Remarks** 

# For more information about this symposium and to register on-line, please visit the CCRN website at www.ccrnmd.com



## THIS EVENT HAS BEEN MADE POSSIBLE THROUGH GRANT SUPPORT TO THE CANADIAN CARDIOVASCULAR RESEARCH NETWORK FROM THE FOLLOWING SPONSORS:

Li Ka Shing Knowledge Institute, Novartis Pharmaceuticals Canada Inc., Sanofi-aventis and Bristol-Myers Squibb (joint venture), Abbott, Merck Frosst, AstraZeneca Canada Inc.

This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. It is approved by the Canadian Cardiovascular Society for a maximum of 2 credits. This accredited symposium was co-developed with the Canadian Cardiovascular Society and the Canadian Cardiovascular Research Network and was planned to ensure the evidence presented is valid, objective and balanced.

Through an agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Canadian Cardiovascular Society designated this live educational activity for a maximum of 2 AMA PRA category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.



for a maximum of 2 hours of Section 1 credits.